ACOR

ACOR’s Neuronex acquisition worth up to $133M; hinges on epilepsy drug

Central nervous system therapies company Neuronex is being acquired by Acorda Therapeutics (NASDAQ:ACOR) in a deal valued at up to $133 million, yielding to Acorda a novel epilepsy treatment nearly ready for filing with the U.S. Food and Drug Administration. But privately held Neuronex gets just $2 million up front. Critical to the Morrisville, North […]

Medtronic spine, traumatic brain injury deal has $35 million potential (and more)

Medtronic (NYSE:MDT) has licensed a compound for spinal cord and traumatic brain injury that could net the Minnesota-based maker of new innovative medical devices up to $35 million before commercialization. New York’s Acorda Therapeutics (NASDAQ:ACOR) said it paid an initial $3 million for the compound, a proprietary magnesium formulation called AC105. It would pay Medtronic […]